MonoRab™ Anti-Pembrolizumab Antibody(129G11B9), mAb, Rabbit

该产品已下架。

Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. GenScript MonoRab™ Anti-Pembrolizumab Antibody (129G11B9), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Pembrolizumab.

产品编号	A01852
规格	定制报价

联系我们

产品概述

Specificity	The product is specific for Pembrolizumab. The antibody is recommended as a capture antibody in a pharmacokinetic (PK) bridging assay with detection antibody GenScript, A01853-40, Anti-Pembrolizumab Antibody (90G12F8), mAb, Rabbit.
Host Species	Rabbit
Immunogen	Pembrolizumab

产品属性

Concentration	0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide. (It could be customized for bulk order)
Reconstitution	Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.
Purification	Protein A affinity column
Clone ID	129G11B9

技术背景

Target Background

Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells.
GenScript MonoRab™ Anti-Pembrolizumab Antibody (129G11B9), mAb, Rabbit is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a rabbit immunized with Pembrolizumab.